导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.45% | 2315/4772 |
| 近一周 | -0.80% | 1963/5490 |
| 近一月 | -3.74% | 2593/5407 |
| 近一季 | -3.11% | 2415/5201 |
| 近半年 | -1.93% | 1768/4918 |
| 近一年 | 4.72% | 1796/4355 |
| 近两年 | 53.07% | 1386/2950 |
| 近三年 | 35.24% | 832/2241 |
| 成立以来 | 21.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.36% 3159/4961 |
14.89% 1741/5312 |
- - |
- - |
| 2025 | 24.36% 1794/4813 |
0.84% 1756/3635 |
1.27% 2398/4076 |
21.29% 1820/4524 |
0.41% 2013/4813 |
| 2024 | 18.10% 627/3463 |
2.90% 672/2808 |
-0.70% 822/3014 |
17.46% 1186/3129 |
-1.59% 1759/3463 |
| 2023 | -9.10% 1106/2656 |
3.83% 1115/2280 |
-3.86% 932/2385 |
-2.70% 722/2515 |
-6.41% 1757/2655 |
| 2022 | -18.65% 736/2207 |
-13.39% 750/1919 |
8.15% 383/2016 |
-14.29% 1063/2113 |
1.33% 1299/2208 |
| 2021 | -1.49% 804/1822 |
-3.12% 762/1255 |
3.47% 971/1330 |
-4.31% 699/1466 |
2.70% 534/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 诺安中证A100指数C VS. 长安沪深300非周期A(740101) |